Suppr超能文献

10%艾氟康唑外用溶液治疗老年人甲癣的疗效与安全性:两项3期随机试验的事后分析

Efficacy and Safety of Efinaconazole 10% Topical Solution for Treatment of Onychomycosis in Older Adults: A Post Hoc Analysis of Two Phase 3 Randomised Trials.

作者信息

Lipner Shari R, Gupta Aditya K, Joseph Warren S, Elewski Boni, Guenin Eric, Vlahovic Tracey C

机构信息

Weill Cornell Medicine, New York, New York, USA.

Mediprobe Research Inc., London, Ontario, Canada.

出版信息

Mycoses. 2025 May;68(5):e70069. doi: 10.1111/myc.70069.

Abstract

BACKGROUND

Onychomycosis is common in older adults and can be difficult to treat owing to slower nail growth, increased nail thickness, comorbidities, and concomitant medications. Oral treatments can be complicated by contraindications, drug-drug interactions, and adverse effects. Topical treatments such as efinaconazole 10% solution may be beneficial for treating older adults.

OBJECTIVES

To evaluate the efficacy/safety of efinaconazole 10% solution in adults aged ≥ 65 years with toenail onychomycosis.

PATIENTS/METHODS: In two multicenter, double-blind, phase 3 studies (NCT01008033; NCT01007708), patients with mild to moderate toenail onychomycosis were randomised (3:1) to once-daily efinaconazole or vehicle for 48 weeks, with a 4-week follow-up. Pooled data for participants aged ≥ 65 years were analysed post hoc (n = 162 efinaconazole, n = 56 vehicle). The primary endpoint was complete cure (0% involvement of target toenail plus mycologic cure [negative KOH and fungal culture]) at week 52. Treatment-emergent adverse events (TEAEs) were assessed throughout.

RESULTS

At week 52, a significantly greater proportion of older adults (aged 65-71 years) achieved complete cure with efinaconazole than vehicle (13.6% vs. 3.6%; p < 0.05). Complete/almost complete cure rate was also significantly greater (≤ 5% involvement and mycologic cure; 19.1% vs. 5.4%; p = 0.01), and over half (59.2%) of participants achieved mycologic cure with efinaconazole versus 12.5% with vehicle (p < 0.001). Treatment-related TEAE rates with efinaconazole were low (6.0%) and similar to the overall study population.

CONCLUSIONS

Efinaconazole 10% solution showed similar efficacy/safety in participants aged ≥ 65 years to the overall phase 3 population, despite potential age-related nail changes. These results demonstrate the benefits of efinaconazole in older patients with onychomycosis.

摘要

背景

甲癣在老年人中很常见,由于指甲生长缓慢、指甲增厚、合并症和同时服用的药物,治疗可能很困难。口服治疗可能因禁忌症、药物相互作用和不良反应而变得复杂。外用治疗如10%艾氟康唑溶液可能对治疗老年人有益。

目的

评估10%艾氟康唑溶液治疗65岁及以上成人趾甲甲癣的疗效/安全性。

患者/方法:在两项多中心、双盲、3期研究(NCT01008033;NCT01007708)中,轻度至中度趾甲甲癣患者被随机分组(3:1),每天一次使用艾氟康唑或赋形剂,持续48周,并进行4周的随访。对65岁及以上参与者的汇总数据进行事后分析(艾氟康唑组n = 162,赋形剂组n = 56)。主要终点是在第52周时完全治愈(目标趾甲受累为0%加上真菌学治愈[氢氧化钾和真菌培养阴性])。在整个过程中评估治疗中出现的不良事件(TEAE)。

结果

在第52周时,使用艾氟康唑的老年人(65 - 71岁)实现完全治愈的比例显著高于使用赋形剂的老年人(13.6%对3.6%;p < 0.05)。完全/几乎完全治愈率也显著更高(受累≤5%且真菌学治愈;19.1%对5.4%;p = 0.01),超过一半(59.2%)的参与者使用艾氟康唑实现真菌学治愈,而使用赋形剂的为12.5%(p < 0.001)。艾氟康唑治疗相关的TEAE发生率较低(6.0%),与整个研究人群相似。

结论

尽管存在与年龄相关的指甲变化,但10%艾氟康唑溶液在65岁及以上参与者中的疗效/安全性与整个3期人群相似。这些结果证明了艾氟康唑对老年甲癣患者的益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f827/12093445/1f677d613b92/MYC-68-e70069-g005.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验